Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2007;31(4):310-5.
doi: 10.1016/j.cdp.2007.07.005.

The UGT2B17 gene deletion polymorphism and risk of prostate cancer. A case-control study in Caucasians

Carla J Gallagher  1 , Fred F Kadlubar, Joshua E Muscat, Christine B Ambrosone, Nicholas P Lang, Philip Lazarus
Affiliations

The UGT2B17 gene deletion polymorphism and risk of prostate cancer. A case-control study in Caucasians

Carla J Gallagher et al. Cancer Detect Prev. 2007.

Abstract

Background: UDP-glucuronosyltransferase (UGT) 2B17 is a phase II metabolizing enzyme that mediates the glucuronidation of C(19) steroids. A deletion polymorphism in the UGT2B17 gene is associated with a substantial reduction in glucuronidation activity in vitro.

Methods: We examined the association between the UGT2B17 deletion polymorphism and the risk of incident prostate cancer in a population-based study from central Arkansas that included 411 Caucasian cases and 397 Caucasian controls. We developed a novel high-throughput procedure that uses real-time PCR and allelic discrimination for genotyping analysis.

Results: The prevalence of the UGT2B17 deletion [(0/0)] was 12% in the controls, which was consistent with previous population estimates and with Hardy Weinberg equilibrium. There was no association between the UGT2B17 deletion polymorphism and prostate cancer risk in unconditional logistic regression analysis. Compared to the wild-type group (+/+), the adjusted odds ratio (OR) was 0.89 (95% CI=0.55-1.45) for the homozygous deletion (0/0), and the OR was 0.99 (95% CI=0.73-1.35) for the heterozygote group (+/0).

Conclusion: These findings show that the UGT2B17 deletion polymorphism is not associated with prostate cancer risk in Caucasians.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Gene structure and primer and probe locations for the UGT2B17 multiplex real-time PCR assay. The roman numerals I–VI indicate the exons of the UGT2B17 gene on the wild-type allele. The deletion allele is shown below the wild-type allele indicating the 120 kb that are deleted, including the entire UGT2B17 gene. Red arrows indicate the primers that will amplify the deletion allele and the red bar (with fluorescent label Joe) indicates the deletion probe. Blue arrows indicate the primers that will amplify exon 1 of UGT2B17 from the wild-type allele and the blue bar (with fluorescent label Fam) indicates the deletion probe.
See this image and copyright information in PMC

Comment in

References

    1. Gueraud F, Paris A. Glucuronidation: a dual control. Gen Pharmacol. 1998;31(5):683–688. - PubMed
    1. Ren Q, Murphy SE, Zheng Z, Lazarus P. O-Glucuronidation of the lung carcinogen 4-(methylnitrosamino)-1- (3-pyridyl)-1-butanol (NNAL) by human UDP-glucuronosyltransferases 2B7 and 1A9. Drug Metab Dispos. 2000;28(11):1352–1360. - PubMed
    1. Tephly TR, Burchell B. UDP-glucuronosyltransferases. a family of detoxifying enzymes. Trends Pharmacol Sci. 1990;11(7):276–279. - PubMed
    1. Beaulieu M, Levesque E, Hum DW, Belanger A. Isolation and characterization of a novel cDNA encoding a human UDP-glucuronosyltransferase active on C19 steroids. J Biol Chem. 1996;271(37):22855–22862. - PubMed
    1. Hsing AW, Reichardt JK, Stanczyk FZ. Hormones and prostate cancer. current perspectives and future directions. Prostate. 2002;52(3):213–235. - PubMed

Publication types

Substances